Sage, Biogen

Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
Sage Rejects Biogen's $469 Million Takeover Offer, Says Offer Undervalues Company
(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
The proposal sought to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, a valuation deemed insufficient by the Board. Meanwhile, Sage remains committed to its mission of making ZURZUVAE the standard treatment for women with postpartum depression as the Board evaluates potential strategic opportunities.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage Therapeutics,
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. | Sage Therapeutics has brought a lawsuit seeking a temporary restraining order against Biogen shortly after receiving an "unsolicited" offer from its neuroscience partner.
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.
Sage Hill girls basketball emerges as candidate for CIF-SS Open Division playoffs
The Lightning are eighth in the section’s latest computer-generated power ratings, a key spot since the Open has featured ...
Lyon coach Pierre Sage has been fired despite putting the French league club back on track
Lyon coach Pierre Sage has been fired despite leading the French league club out of a crisis last season and having the team ...
Sage Group rises Tuesday, still underperforms market
Sage Group PLC closed 1.08% below its 52-week high of £13.42, which the company achieved on January 22nd.
American Banker13h
Sage Capital Bank hopes digital banking upgrade fosters growth
A partnership with fintech Apiture will give the bank new online and mobile banking services by the end of 2025.
Lyon sack coach Sage amid poor run
Olympique Lyonnais have sacked coach Pierre Sage, the French Ligue 1 club announced on Tuesday, after a winless run of five ...
Nemanja Matić open to Lyon exit following Pierre Sage’s dismissal
Serbian midfielder Nemanja Matić (36) would be open to a last-minute Lyon exit following the dismissal of head coach Pierre ...
KLCC14h
Oregon delays sage grouse habitat maps for Grant County after community backlash
An undated photo of a male great western sage grouse. The Oregon Land Conservation and Development Commission decides to ...
Ligue 1: Lyon Sack Head Coach Pierre Sage After Nantes Draw Leaves Them 17 Points Adrift Of Leaders PSG
Sage joined Lyon in November 2023 in an interim role, which was made permanent with a contract until 2026 after he led them ...